Gastric & esophageal cancers are collectively known as gastroesophageal (GE) cancer and are among the leading causes of cancer deaths worldwide. Patients with early-stage GE cancer may experience dyspepsia, anorexia, dysphagia, weight loss, or abdominal pain and are often prescribed a combination of surgery & chemotherapy, with or without radiation.
There are multiple strategies for delivering neoadjuvant & adjuvant chemotherapies; however no existence of any optimal strategy. Surgery remains crucial for esophageal SCC (squamous cell carcinoma), whereas, in metastatic or unresectable diseases, there's a limited impact of traditional SOC (standard-of-care) treatments on patient outcomes.
The Global Gastroesophageal Cancer Market is projected to grow at around 15.8% CAGR during the forecast period, i.e., 2022-27. The growth of the market is driven primarily by the growing number of tobacco & alcohol consumers, lifestyle disorders, and the increasing prevalence of gastroesophageal reflux diseases (GERDs) & obesity.
|Study Period||Historical Data: 2017-20|
|Base Year: 2021|
|Forecast Period: 2022-27|
|Regions Covered||North America: The US, Canada, Mexico|
|Europe: Germany, The UK, Germany, France, Italy, Spain, Rest of Europe|
|Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific|
|South America: Brazil, Rest of Latin America|
|Middle East & Africa: South Africa, GCC, Rest of Middle East & Africa|
|Key Companies Profiled||
AstraZeneca PLC, Amgen Inc., Bayer AG, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Others
|Unit Denominations||USD Million/Billion|
The epidemiology of GE cancer has significantly transformed over several years, especially across developed countries. Since there are no early symptoms, esophageal cancer is diagnosed mainly at advanced stages. It owes prominently to heavy smoking & alcohol usage and growing instances of diseases like gastroesophageal reflux, obesity, & gastric ulcer, among others, which increase the risk of developing gastric cancer.
Even with significant developments in multimodality treatments, the prognosis for GE cancer is still inadequate, with a below 20% 5-year survival rate. However, rapid approvals for the combined use of systemic therapies & new targeted agents as first-line treatments are projected to generate growth opportunities for the Global Gastroesophageal Cancer Market through 2027.
Additionally, the remarkable efficacy of immune checkpoint inhibitors, especially Opdivo & Keytruda, would further augment the market expansion in the nearer future. Various targeted therapies in late-stage development, coupled with easy insurance reimbursements, are also anticipated to boost the market in the years to come.
However, aspects like the high costs of therapies and their adverse effects like mouth sores, loss of appetite, hair loss, diarrhea, etc., which can greatly damage some vital nerves of the body, might hinder the growth of the Global Gastroesophageal Market during 2022-27.